96 patents
Page 4 of 5
Utility
Activating pyruvate kinase R
27 Jul 21
This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.
Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Gary Marshall, Lorna Mitchell, David Richard, Zhongguo Wang
Filed: 1 May 20
Utility
Activating Pyruvate Kinase R and Mutants Thereof
22 Jul 21
The disclosure provides chemical compounds useful as activators of PKR.
David R. Lancia, JR., Gary Gustafson, Neal Green, Lorna Mitchell, Anna Ericsson, David Richard
Filed: 6 Apr 21
Utility
Novel Compounds and Compositions for Inhibition of Fasn
15 Jul 21
Kenneth W. Bair, David R. Lancia, JR., Hongbin LI, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Mark J. Tebbe
Filed: 26 Feb 21
Utility
Fused Bicyclic Compounds Useful As Ubiquitin-specific Peptidase 30 Inhibitors
1 Jul 21
Matthew W. MARTIN, Alexandre Joseph BUCKMELTER
Filed: 16 May 19
Utility
Inhibiting Mutant IDH-1
1 Jul 21
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 16 May 19
Utility
Solid Forms of ((S)-5-((1-(6-CHLORO-2-OXO-1,2-DIHYDROQUINOLIN-3-YL)ETHYL)AMINO)-1-METHYL-6-OXO-1,6-DIHYDROPYRIDINE-2-CARBONITRILE
17 Jun 21
The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
George P. Luke, Pratik Sheth
Filed: 24 Feb 21
Utility
Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
25 May 21
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
Filed: 4 Jun 19
Utility
Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
25 May 21
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 30 Jul 19
Utility
Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
25 May 21
Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
Filed: 20 Mar 18
Utility
Activating pyruvate kinase R and mutants thereof
11 May 21
The disclosure provides chemical compounds useful as activators of PKR.
David R. Lancia, Jr., Gary Gustafson, Neal Green, Lorna Mitchell, Anna Ericsson, David Richard
Filed: 19 Sep 19
Utility
Compounds and compositions for inhibition of FASN
4 May 21
Kenneth W. Bair, David R. Lancia, Jr., Hongbin Li, James Loch, Wei Lu, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Mark J. Tebbe
Filed: 20 May 20
Utility
Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
30 Mar 21
The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
George P. Luke, Pratik Sheth
Filed: 25 Nov 19
Utility
Treating Patients Harboring an Isocitrate Dehydrogenase 1 (IDH-1) Mutation
25 Mar 21
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 4 Dec 20
Utility
PYRIDIN-2(1H)-ONE Quinolinone Derivatives As Mutant-isocitrate Dehydrogenase Inhibitors
18 Mar 21
Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
Filed: 23 Nov 20
Utility
Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
9 Feb 21
David Joseph Guerin, Kenneth W. Bair, Justin A. Caravella, Stephanos Ioannidis, Jr., David R. Lancia, Jr., Hongbin Li, Steven Mischke, Pui Yee Ng, David Richard, Shawn E. R. Schiller, Tatiana Shelekhin, Zhongguo Wang
Filed: 13 Feb 17
Utility
Inhibiting Fatty Acid Synthase (Fasn)
28 Jan 21
The present disclosure is directed to inhibitors of FASN.
Matthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
Filed: 15 Sep 20
Utility
Compositions for Activating Pyruvate Kinase
21 Jan 21
Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, JR., Lorna Mitchell, Tatiana Shelekhin
Filed: 2 Oct 20
Utility
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
12 Jan 21
Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
Filed: 12 Dec 19
Utility
Treating Sickle Cell Disease with a Pyruvate Kinase R Activating Compound
30 Dec 20
Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD).
Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, David R. LANCIA, Jr., Gary MARSHALL, Lorna MITCHELL, David RICHARD, Zhongguo WANG, Sanjeev FORSYTH, Patrick F. KELLY, Madhu MONDAL, Maria RIBADENEIRA, Patricia SCHROEDER
Filed: 31 Aug 20
Utility
Inhibiting fatty acid synthase (FASN)
28 Dec 20
The present disclosure is directed to inhibitors of FASN.
Matthew W. Martin, Mary-Margaret Zablocki, Scot Mente, Christopher Dinsmore, Zhongguo Wang, Xiaozhang Zheng
Filed: 9 Oct 19